Back to Search
Start Over
Sonidegib in the Treatment of Locally Advanced Basal Cell Carcinoma
- Source :
- Actas Dermo-Sifiliográficas (English Edition). 112:295-301
- Publication Year :
- 2021
- Publisher :
- Elsevier BV, 2021.
-
Abstract
- Sonidegib is an antagonist of the transmembrane protein Smoothened in the Hedgehog signaling pathway. It is indicated for the treatment of locally advanced basal cell carcinoma (BCC) that is not amenable to curative surgery or radiotherapy. Sonidegib's efficacy and safety were demonstrated in the phase 2 BOLT trial, where 61% (95% CI, 48-72%) of patients with locally advanced BCC treated with sonidegib 200 mg achieved an objective response to treatment with a mean time to response of 4 months. The median duration of response was 26.1 months and the median progression-free survival was 22.1 months. The most common adverse events were muscle spasms (54.4%), hair loss (49.4%), and loss of taste (44.3%); most events were grade 1 or 2. In this review, we summarize the main findings on the efficacy, safety, and tolerability of sonidegib and discuss the management of locally advanced BCC with this drug.
- Subjects :
- Oncology
medicine.medical_specialty
Histology
business.industry
medicine.medical_treatment
Antagonist
Dermatology
medicine.disease
Sonidegib
Pathology and Forensic Medicine
Radiation therapy
030207 dermatology & venereal diseases
03 medical and health sciences
chemistry.chemical_compound
0302 clinical medicine
Hair loss
Tolerability
chemistry
030220 oncology & carcinogenesis
Internal medicine
medicine
Basal cell carcinoma
Smoothened
Adverse effect
business
Subjects
Details
- ISSN :
- 15782190
- Volume :
- 112
- Database :
- OpenAIRE
- Journal :
- Actas Dermo-Sifiliográficas (English Edition)
- Accession number :
- edsair.doi...........1c72f3f1ecb617b82c3e2243e2aefedd